363. National Burden of Candidemia, United States, 2017
Session: Poster Abstract Session: Fungal Disease: Management and Outcomes
Thursday, October 4, 2018
Room: S Poster Hall


Candidemia is a common healthcare-associated bloodstream infection associated with high morbidity and mortality. No current estimates exist for understanding its burden in the United States.


In 2017, CDC’s Emerging Infections Program (EIP) performed laboratory- and active population-based candidemia surveillance in 45 counties in 9 states (CA, CO, GA, MD, MN, NM, NY, OR, TN), encompassing ~17 million persons. A case was defined as Candida species isolated from blood in a surveillance area resident.  EIP site staff reviewed medical records to collect demographic and clinical data. Using 2016 U.S. census data, we created weighted estimates of national and regional incidence rates and mortality in persons with candidemia (defined as death from any cause within 7 days of incident candidemia).


A total of 1,226 candidemia cases were identified in 2017. We estimated 23,000 candidemia cases (95% CI 20,000-25,000) occurred in the U.S. in 2017. Overall estimated incidence was 7.0/100,000 persons, with elevated rates in adults ≥65 years (20.3/100,000), males (8.0/100,000), and people of Black race (12.6/100,000) (Table). Incidence was highest in the South Atlantic region (8.0/100,000) and lowest in the Pacific (6.0/100,000). Estimated number of deaths was 3,000 (1,000-5,000).


Our analysis highlights the substantial burden of candidemia in the U.S. Because candidemia is only one form of invasive candidiasis, the true burden of invasive infections due to Candida species is likely higher. Ongoing surveillance can support future burden estimates and help assess the impact of prevention interventions.

Sharon Tsay, MD1, Sabrina Williams, MPH1, Yi Mu, PhD2, Erin Epson, MD3, Helen Johnston, MPH4, Monica M. Farley, MD, FIDSA5, Lee H. Harrison, MD6, Brittany Vonbank, MPH7, Sarah Shrum, MPH8, Ghinwa Dumyati, MD, FSHEA9, Alexia Zhang, MPH10, William Schaffner, MD, FIDSA, FSHEA11, Shelley Magill, MD, PhD12 and Snigdha Vallabhaneni, MD, MPH1, (1)Mycotic Diseases Branch, Centers for Disease Control and Prevention, Atlanta, GA, (2)Division of Healthcare Quality Promotion, Centers for Disease Control and Prevention, Atlanta, GA, (3)Healthcare-Associated Infections Program, California Department of Public Health, Richmond, CA, (4)Colorado Department of Public Health and Environment, Denver, CO, (5)Department of Medicine, Emory University School of Medicine and Atlanta VA Medical Center, Atlanta, GA, (6)Maryland Emerging Infections Program, Pittsburg, PA, (7)Minnesota Department of Health, St. Paul, MN, (8)New Mexico Department of Health, Santa Fe, NM, (9)NY Emerging Infections Program, Center for Community Health and Prevention, University of Rochester Medical Center, Rochester, NY, (10)Oregion Emerging Infections Program, Portlant, OR, (11)Vanderbilt University School of Medicine, Nashville, TN, (12)Centers for Disease Control and Prevention, Atlanta, GA


S. Tsay, None

S. Williams, None

Y. Mu, None

E. Epson, None

H. Johnston, None

M. M. Farley, None

L. H. Harrison, None

B. Vonbank, None

S. Shrum, None

G. Dumyati, None

A. Zhang, None

W. Schaffner, None

S. Magill, None

S. Vallabhaneni, None

Findings in the abstracts are embargoed until 12:01 a.m. PDT, Wednesday Oct. 3rd with the exception of research findings presented at the IDWeek press conferences.